Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Infectious Disease
•
General Infectious Disease
Do you routinely recommend an immunodeficiency work up in patients with ARDS due to influenza infection who develop invasive pulmonary aspergillosis?
Related Questions
How do you utilize (1,3)-beta-D-glucan in CSF for diagnosing and monitoring non-cryptococcal CNS fungal infections?
In what scenarios outside of cryptococcal meningitis do you use flucytosine as adjunctive antifungal therapy?
Do you use metronidazole twice daily dosing for routine anaerobic coverage such as non-CNS, H. pylori, C. diff, or parasitic infections?
In what situations would you treat a corynebacterium positive blood culture as a true pathogen compared to a contaminant?
In a patient with a history of seropositive erosive RA who has undergone treatment for a periprosthetic joint infection and currently has an antibiotic spacer in place with clinical improvement, what is the appropriate timing and strategy for restarting DMARDs and/or biologic therapy to balance infection risk with RA disease control?
What is your approach in managing patients with suspected super-infected pancreatic pseudocysts that are not yet mature enough for drainage?
What specific clinical signs or epidemiological indicators do you prioritize for early identification of Bartonella quintana infection?
What role could emerging technologies, such as antimicrobial coatings or biofilm-disrupting agents, play in reducing the incidence of CIED infections?
Do you recommend low or intermediate dosing of TMP-SMX over high dosing for the initial treatment of non-disseminated pulmonary nocardiosis?
In light of recent measles outbreaks in the US, would you recommend an MMR booster for an immunocompetent patients born before 1957?
